The APAC in situ hybridization market is projected to witness tremendous growth over the forecast period due to the increasing demand for diagnostics testing, as well as the rising prevalence of chronic diseases. In situ hybridization (ISH) is a technique used to identify the presence of specific nucleic acid sequences in a tissue or cell sample. This technique is used to detect the presence or absence of mRNA or other nucleic acid molecules in a sample.

Currently, APAC In situ Hybridization Market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. The growth is largely driven by increasing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of

The APAC in situ hybridization market is driven by the increasing demand for diagnostics testing and the rising prevalence of chronic diseases. In addition, technological advancements, such as the development of digital ISH, have further fueled the market growth. The increasing number of mergers and acquisitions in the region has also contributed to the growth of the market. Furthermore, the growing investments by major players are expected to create numerous opportunities for the market.

The APAC in situ hybridization market is segmented by type, application, end user, and geography. By type, the market is segmented into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). By application, the market is segmented into oncology, infectious diseases, and others. By end user, the market is segmented into hospitals, research centers, diagnostic laboratories, and others.

The report provides detailed insights into the APAC in situ hybridization market. It covers the key drivers, trends, opportunities, and challenges that are expected to affect the market growth over the forecast period. The report provides a comprehensive analysis of the market, with a focus on the competitive landscape, market dynamics, regional analysis, and other key segments. The report also provides an in-depth analysis of the key players operating in the market and their strategies to gain a competitive edge.

The major players in the Asia Pacific In situ Hybridization Market are Abbott Laboratories (US), Abcam (UK), Abnova Corporation (Taiwan), Agilent Technologies (US), Bio SB (US), Biocare Medical (US), BioGenex Laboratories (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), BioView (Israel), Danaher (US), Enzo Biochem (US), F. Hoffmann-La Roche (Switzerland), Merck (Germany), NeoGenomics Laboratories (US), OpGen (US), PerkinElmer (US), QIAGEN (Germany), Thermo Fisher Scientific (US), and ZytoVision (Germany).

Request for assumptions & how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=51341505

The APAC In situ Hybridization Market is expected to witness a high growth rate during the forecast period of 2022-2027, due to several factors such as the increasing R&D investments, the growing prevalence of chronic diseases, the growing prevalence of infectious diseases, the increasing adoption of advanced technologies, and the rising demand for personalized medicine. Additionally, the growing demand for cost-effective diagnostic solutions and the presence of a large patient population are some of the major drivers of the APAC in situ hybridization market. Furthermore, the rising geriatric population and the increasing awareness about personalized medicine are expected to fuel the growth of the APAC in situ hybridization market.

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51341505

Recent Developments

In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.
Content Source:

https://www.marketsandmarkets.com/Market-Reports/apac-in-situ-hybridization-market-51341505.html

https://www.prnewswire.com/news-releases/apac-in-situ-hybridization-market-worth-744-million-by-2027---exclusive-report-by-marketsandmarkets-301717501.html